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Background
Platinum-based doublets are standard of care (SoC) first-
line treatment for advanced NSCLC, but durable benefit is
observed infrequently, with resistance to chemotherapy
invariably developing. The blockade of immune check-
points is a promising novel approach in cancer treatment.
Blocking co-inhibitory molecules, such as programmed
cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated
antigen-4 (CTLA-4), from binding with their ligands can
restore T-cell responses against tumors. As these pathways
are non-redundant, dual targeting may have additive or
synergistic antitumor activity. Durvalumab (MEDI4736) is
a selective, high affinity human IgG1 mAb that blocks pro-
grammed cell death ligand-1 (PD-L1) binding to PD-1
(IC50 0.1 nM) and CD80 (IC50 0.04 nM), and tremelimu-
mab is a selective human IgG2 mAb inhibitor of CTLA-4.
Durvalumab monotherapy has shown durable responses
in a NSCLC cohort from a Phase I/II study in heavily pre-
treated patients with solid tumors[1] and durvalumab plus
tremelimumab has shown encouraging clinical activity and
a manageable safety profile in a Phase Ib study in patients
with NSCLC[2]. A comprehensive clinical development
program of durvalumab +/- tremelimumab in NSCLC is
underway. MYSTIC (NCT02453282) is a global Phase III
study to determine the efficacy and safety of durvalumab
plus tremelimumab combination therapy or durvalumab
monotherapy versus SoC platinum-based doublets in the
first-line treatment of patients with advanced or metastatic
NSCLC.
Methods
In this randomized, open-label, multicenter, global, Phase
III study, 675 immunotherapy- and chemotherapy-naïve
patients with advanced or metastatic (Stage IV) NSCLC
who are wild-type for epidermal growth factor receptor
(EGFR) and anaplastic lymphoma kinase (ALK) will be
randomized (1:1:1) to receive durvalumab (20 mg/kg IV
every 4 weeks for up to 12 months) plus tremelimumab
(1 mg/kg IV every 4 weeks for up to 4 doses); durvalumab
monotherapy (20 mg/kg IV every 4 weeks for up to 12
months); or SoC chemotherapy (Figure 1). Stratification
factors are PD-L1 status and histology. The primary end-
point is progression-free survival (PFS) using investigator
assessments (RECIST v1.1). Secondary endpoints will
further assess objective response rate, duration of
response, proportion of patients alive and progression free
at 12 months, time from randomization to second pro-
gression, and overall survival (OS); safety (CTCAE v4.03)
and tolerability; health-related quality of life; pharmacoki-
netics; and immunogenicity. Exploratory outcomes include1Columbia University Medical Center, New York, NY, USA
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